CV 6504

Drug Profile

CV 6504

Latest Information Update: 03 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Nonindustrial source; Takeda
  • Class Antineoplastics
  • Mechanism of Action 5-lipoxygenase inhibitors; Oxygen radical scavengers; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Nephritis; Pancreatic cancer

Most Recent Events

  • 07 Dec 2000 Phase-II clinical trials for Pancreatic cancer in England (Unknown route)
  • 07 Dec 2000 A phase II study has been added to the Cancer therapeutic trials and pharmacokinetics sections
  • 11 Oct 2000 Discontinued-Preclinical for Cancer in England (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top